Circulating tumor cells correlating with Ki-67 predicts the prognosis of bladder cancer patients

Liu, Jie; Ma, Cailing; Li, Xiaohang; Li, Anan; Wang, Zhiyong

doi:10.1007/s11255-022-03406-y

Cited by 8 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although our regimen increased and decreased tumour CK5 and GATA3, respectively, suggesting a luminal-to-basal transition, studies with larger sample size are needed. In addition, Ki67 expression appeared to be associated with UBC aggressiveness evidenced by higher grade, muscle invasion, and increased postoperative circulating tumour cells 35 , 36 . All three patients in our study had relatively high levels of Ki67 and all responded well to the treatment, suggesting the levels of Ki67 might be an indicator of responsiveness.…”

Section: Discussionmentioning

confidence: 94%

Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series

Wang,

Wang

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Introduction and importance: The feasibility of combined tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle invasive bladder cancer (MIBC) remains to be investigated. Case presentation: The neoadjuvant treatment not only shrunk tumors significantly but also lowered their stages from T4bN1M0, T3N0M0, and T3bN0M0 to pT1, pT0 and pTis, respectively. The treatment suppressed tumor cell proliferation and promoted luminal-to-basal transition. Clinical Discussion: MIBC is an aggressive bladder cancer with poor prognosis. All three patients with MIBC benefited greatly from the neoadjuvant regimen (tislelizumab + gemcitabine + cisplatin). It appears that the effect of the treatment is independent of the levels of programmed death-ligand 1 nor the subtype of urothelial bladder cancer. Conclusion: Combination of tislelizumab with gemcitabine and cisplatin appeared to be a safe and efficacious neoadjuvant therapy for MIBC.

show abstract

Section: Discussionmentioning

confidence: 94%

Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series

Wang,

Wang

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

“…Similarly, Liu et al. showed that elevated expression of Ki-67 predicted bad prognosis in BCa patients by collecting 84 patients who underwent surgery ( 26 ). Culpan et al.…”

Section: Discussionmentioning

confidence: 99%

“…By collecting 213 patients with papillary BCa, March-Villalba et al revealed that the Ki-67 index improves the prediction of recurrence and PFS in papillary BCa (23). Similarly, Liu et al showed that elevated expression of Ki-67 predicted bad prognosis in BCa patients by collecting 84 patients who underwent surgery(26). Culpan et al included 101 patients with primary BCa, and the results suggested that, in pT1 BCa patients, the biomarker Ki-67 significantly predicted recurrence-free, progression-free, and cancer-specific survival (27).…”

mentioning

confidence: 99%

Prediction of Ki-67 expression in bladder cancer based on CT radiomics nomogram

Feng,

Zhou,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectivesThis study aimed to create and validate a radiomics nomogram for non-invasive preoperative Ki-67 expression level prediction in patients with bladder cancer (BCa) using contrast-enhanced CT radiomics features.MethodsA retrospective analysis of 135 patients was conducted, 79 of whom had high levels of Ki-67 expression and 56 of whom had low levels. For the dimensionality reduction analysis, the best features were chosen using the least absolute shrinkage selection operator and one-way analysis of variance. Then, a radiomics nomogram was created using multiple logistic regression analysis based on radiomics features and clinical independent risk factors. The performance of the model was assessed using the Akaike information criterion (AIC) value, the area under the curve (AUC) value, accuracy, sensitivity, and specificity. The clinical usefulness of the model was assessed using decision curve analysis (DCA).ResultsFinally, to establish a radiomics nomogram, the best 5 features were chosen and integrated with the independent clinical risk factors (T stage) and Rad-score. This radiomics nomogram demonstrated significant correction and discriminating performance in both the training and validation sets, with an AUC of 0.836 and 0.887, respectively. This radiomics nomogram had the lowest AIC value (AIC = 103.16), which was considered to be the best model. When compared to clinical factor model and radiomics signature, DCA demonstrated the more value of the radiomics nomogram.ConclusionEnhanced CT-based radiomics nomogram can better predict Ki-67 expression in BCa patients and can be used for prognosis assessment and clinical decision making.

show abstract

“…If not recognized by immune cells, CTCs will extravasate and form metastasis [ 65 ]. CTCs are associated with poor prognosis in hepatocellular carcinoma [ 66 ], lung [ 67 , 68 ], and bladder cancer [ 69 ]. Therefore, their early diagnosis and eradication may prolong patients’ survival [ 70 ].…”

Section: Targeting Circulating Tumor Cellsmentioning

confidence: 99%

Targeting circulating tumor cells to prevent metastases

Gostomczyk,

Marsool,

Tayyab

et al. 2023

Human Cell

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are cancer cells that detach from the primary tumor, enter the bloodstream or body fluids, and spread to other body parts, leading to metastasis. Their presence and characteristics have been linked to cancer progression and poor prognosis in different types of cancer. Analyzing CTCs can offer valuable information about tumors’ genetic and molecular diversity, which is crucial for personalized therapy. Epithelial-mesenchymal transition (EMT) and the reverse process, mesenchymal-epithelial transition (MET), play a significant role in generating and disseminating CTCs. Certain proteins, such as EpCAM, vimentin, CD44, and TGM2, are vital in regulating EMT and MET and could be potential targets for therapies to prevent metastasis and serve as detection markers. Several devices, methods, and protocols have been developed for detecting CTCs with various applications. CTCs interact with different components of the tumor microenvironment. The interactions between CTCs and tumor-associated macrophages promote local inflammation and allow the cancer cells to evade the immune system, facilitating their attachment and invasion of distant metastatic sites. Consequently, targeting and eliminating CTCs hold promise in preventing metastasis and improving patient outcomes. Various approaches are being explored to reduce the volume of CTCs. By investigating and discussing targeted therapies, new insights can be gained into their potential effectiveness in inhibiting the spread of CTCs and thereby reducing metastasis. The development of such treatments offers great potential for enhancing patient outcomes and halting disease progression.

show abstract

Circulating tumor cells correlating with Ki-67 predicts the prognosis of bladder cancer patients

Cited by 8 publications

References 24 publications

Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series

Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series

Prediction of Ki-67 expression in bladder cancer based on CT radiomics nomogram

Targeting circulating tumor cells to prevent metastases

Contact Info

Product

Resources

About